<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="58828">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02073734</url>
  </required_header>
  <id_info>
    <org_study_id>12136-12-081</org_study_id>
    <nct_id>NCT02073734</nct_id>
  </id_info>
  <brief_title>Effects of Preoperative Dexamethasone Study on QOL After Vaginal Reconstructive Surgery for POP</brief_title>
  <official_title>Effects of Preoperative Dexamethasone on Postoperative Quality of Recovery Following Vaginal Reconstructive Surgery: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TriHealth Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TriHealth Inc.</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothesize that preoperative administration of 8 mg IV dexamethasone will
      benefit patients' perceived quality of recovery after surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized controlled trial involving single administration of 8 mg Dexamethasone
      per IV preoperatively among women undergoing vaginal reconstructive surgery for pelvic organ
      prolapse.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">August 2014</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>The primary endpoint will be scores on the 40- item quality of recovery scoring system (QoR-40).</measure>
    <time_frame>up to 20-24 hours after surgery</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The QoR-40 is a validated standardized questionnaire that assesses the dimensions of physical functioning, mental health, cognitive functioning, symptoms, role and social functioning, general health perceptions, sleep and energy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine if dexamethasone has positive impact on other clinical recovery variables such as nausea, vomiting and pain.</measure>
    <time_frame>20-24 hours after surgery</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">62</enrollment>
  <condition>Pelvic Organ Prolapse</condition>
  <condition>PONV</condition>
  <arm_group>
    <arm_group_label>Dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dexamethasone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sterile normal saline solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Dexamethasone 8mg/IV</description>
    <arm_group_label>Dexamethasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women aged 18-81 years old who are scheduled to undergo a major vaginal
             reconstructive surgery, including hysterectomy  with or without hysterectomy

        Exclusion Criteria:

          -  Daily use of steroids or antiemetic agents such as Zofran, Reglan, Compazine and
             Phenargan within one month of surgery

          -  Regional anesthesia for surgical procedure

          -  Chronic pain requiring opioid treatment daily

          -  History of allergy to the study medication

          -  Severe renal and liver disease

          -  Pregnancy

          -  Non English speaking

          -  Psychiatric disorder that will preclude completion of questionnaires

          -  Minor surgery that does not involve overnight admission

          -  Surgery that does not involve hysterectomy or vaginal intraperitoneal apical
             suspension

          -  Hypersensitivity reaction to steroids

          -  Evidence of systemic fungal infection

          -  Evidence of any systemic infection

          -  Uncontrolled diabetes
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>81 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rachel N Pauls, MD</last_name>
    <role>Study Director</role>
    <affiliation>TriHealth Good Samaritan Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rachel N Pauls, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>TriHeath Good Samaritan Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vivian Ghodsi, RN CCRC</last_name>
    <phone>513-853-4213</phone>
    <email>Vivian_Ghodsi@trihealth.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Angela N Fellner, PhD</last_name>
    <phone>513-862-2330</phone>
    <email>Angie_Fellner@trihealth.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Triheath</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45220</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vivian Ghodsi, RN CCRC</last_name>
      <phone>513-853-4213</phone>
      <email>Vivian_Ghodsi@trihealth.com</email>
    </contact>
    <contact_backup>
      <last_name>Angela N Fellner, PhD</last_name>
      <phone>513-862-2330</phone>
      <email>Angie_Fellner@trihealth.com</email>
    </contact_backup>
    <investigator>
      <last_name>Maria Victoria Estanol, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Susan Oakley, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Catrina Crisp, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lauren Westermann, DO</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Steven Kleeman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rachel Pauls, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Donna Mazloomdoost, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 4, 2014</lastchanged_date>
  <firstreceived_date>April 25, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pelvic organ prolapse surgery</keyword>
  <keyword>dexamethasone</keyword>
  <keyword>postoperative nausea and vomiting</keyword>
  <keyword>peroperative administration</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prolapse</mesh_term>
    <mesh_term>Pelvic Organ Prolapse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
